The short version of counterion fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Chemical Abstracts Service Current Contents/Physical, Chemical & Earth Sciences EBSCO databases Embase Food Science and Technology Abstracts FRANCIS Inspec PASCAL Science Citation Index Expanded Scopus According to the Journal Citation Reports, the journal has a 2020 impact factor of 1.986.
The chemical structure of myristicin is similar to some amphetamines, and it may be capable of producing psychoactive effects. Normal levels of intake of myristicin from spices in food is unlikely to cause these effects. Myristicin can be used in the chemical synthesis of amphetamine derivatives such as the designer drug MMDMA that is similar in chemical structure and effect to MDMA. Out of the common spices that contain myristicin, nutmeg has a high relative concentration of the compound, and therefore is used to exploit the effects of myristicin. At a minimum dose of about 5 grams of nutmeg powder, symptoms of nutmeg intoxication can begin to emerge. Nutmeg intoxication may produce dizziness, drowsiness, and confusion, although in higher amounts, it may have effects similar to deliriants. The effects of nutmeg consumed in large doses may involve myristicin: 1–7 hours following ingestion, symptoms include disorientation, giddiness, stupor, and stimulation of the central nervous system leading to euphoria. Also occurring are mild to intense hallucinations (similar to those induced by deliriants: walls and ceiling glitching or breathing), disorientation to time and surroundings, dissociation, feelings of levitation, loss of consciousness, tachycardia, weak pulse, anxiety, and hypertension. Symptoms of nutmeg intoxication further include nausea, abdominal pain, vomiting, minor to severe muscle spasms (severe in extreme overdose), headache, dryness of mouth, mydriasis or miosis, hypotension, shock, and potentially death.
Chan School of Public Health, it is estimated that around 40% of Americans are considered obese, and 18% are considered severely obese as of 2019. Severe obesity is defined as a BMI over 35 in the study. Their projections say that about half of the US population (48.9%) will be considered obese and nearly 1 in 4 (24.2%) will be considered severely obese by 2030. New data in 2024, reveals the U.S. adult obesity rate decreased by about 2% from 2020 to 2023, according to data from the U.S. National Health and Nutrition Examination Survey. Researchers attribute this decline in part to the increasing use of weight loss drugs like Wegovy and Ozempic, now used by 6% of Americans. These medications may be helping to reverse the long-standing rise in obesity rates in the country.
=== Liquid chromatography-liquid chromatography === Two-dimensional liquid chromatography (2D-LC) combines two separate analyses of liquid chromatography into one data analysis. Modern 2D liquid chromatography has its origins in the late 1970s to early 1980s. During this time, the hypothesized principles of 2D-LC were being proven via experiments conducted along with supplementary conceptual and theoretical work. It was shown that 2D-LC could offer quite a bit more resolving power compared to the conventional techniques of one-dimensional liquid chromatography. In the 1990s, the technique of 2D-LC played an important role in the separation of extremely complex substances and materials found in the proteomics and polymer fields of study. Unfortunately, the technique had been shown to have a significant disadvantage when it came to analysis time. Early work with 2D-LC was limited to small portion of liquid phase separations due to the long analysis time of the machinery. Modern 2D-LC techniques tackled that disadvantage head on, and have significantly reduced what was once a damaging feature. Modern 2D-LC has an instrumental capacity for high resolution separations to be completed in an hour or less. Due to the growing need for instrumentation to perform analysis on substances of growing complexity with better detection limits, the development of 2D-LC pushes forward. Instrumental parts have become a mainstream industry focus and are much easier to attain then before.
== S == saprobe – sarcoplasmic reticulum – scientific classification – secondary metabolite – secondary structure – second messenger – seed – seed plant – selection – Semiochemical – sequencing – serum – semen – Sewall Wright - sex linkage – sexual reproduction – sexual selection – shigella – shoot – signal transduction – silk – Sir Charles Lyell – sister chromatid – skeleton – skin cell – sleep – smooth ER – sociobiology – speciation – species – Hans Spemann – sperm – spermatid – spermatogenesis – spermiogenesis – spliceosome – splicing – spore – sporophyte – SSRI – starch – stem – stem cell – Stem cell chip – sticky end – stoma – stomach – streptomycin – structural biology – structural gene – substrate – substrate-level phosphorylation – surface area-to-volume ratio – symbiosis – symbiogenesis – synapomorphy – synapse – syngamy – systematics – systems biology
Sources: en.wikipedia.org
== Applications == Pyrolysis gas chromatography is useful for the identification of involatile compounds. These materials include polymeric materials, such as acrylics or alkyds. The way in which the polymer fragments, before it is separated in the GC, can help in identification. Pyrolysis gas chromatography is also used for environmental samples, including fossil analysis and microplastic detection. Pyrolysis GC is used in forensic laboratories to analyze evidence found in crime scenes such as paints, adhesives, plastics, synthetic fibres and soil extracts.
=== 20th century === During the 20th century, Harold Wolff's vascular theory linked migraine pain to the widening of blood vessels. Ergotamine, one of the principal alkaloids responsible for its antimigraine effects, was isolated from the ergot fungus in 1918. It was first used to treat migraine in 1925. Methysergide was developed in 1959. The first triptan, sumatriptan, was developed in 1988. Other discoveries identified serotonin as an important chemical involved in migraine, leading to the development of serotonin receptor agonists for treatment. Later, the discovery of calcitonin gene-related peptide (CGRP) improved understanding of migraine and led to the development of targeted CGRP-based medicines.
Some types of specialized cell are localized to a particular animal group. Vertebrates for example have specialized, structurally changed cells including muscle cells. The cell membrane of a skeletal muscle cell or of a cardiac muscle cell is termed the sarcolemma. And the cytoplasm is termed the sarcoplasm. Skeletal muscle cells also become multinucleated. Populations of animal groups evolve to become distinct species, where sexual reproduction is isolated. The many species of vertebrates for example have other unique characteristics by way of additional specialized cells. In some species of electric fish for example modified muscle cells or nerve cells have specialized to become electerocytes capable of creating and storing electrical energy for future release, as in stunning prey, or use in electrolocation. These are large flat cells in the electric eel, and electric ray in which thousands are stacked into an electric organ comparable to a voltaic pile. Many animal cells are ciliated and most cells except red blood cells have primary cilia. Primary cilia play important roles in chemosensation and mechanosensation. Each cilium may be "viewed as a sensory cellular antennae that coordinates a large number of cellular signaling pathways, sometimes coupling the signaling to ciliary motility or alternatively to cell division and differentiation." The cilia in other cells are motile organelles, and in the respiratory epithelium play an important role in the movement of mucus.
The top management of Lyons, with its background in the use of mechanical adding machines, saw the necessity of new electrical computers for organising the distribution of cakes and other highly perishable goods. They, therefore, substantially financed the University of Cambridge's Electronic Delay Storage Automatic Calculator (EDSAC) which was the second electronic digital stored-program computer to go into regular service, and built their own programmable digital computers. They became the first user of these in businesses, with the LEO I digital computer: the Lyons Electronic Office I, designed and built by Dr John Pinkerton under the leadership of John Simmons. It handled the company's accounts and logistics. Lyons also included the weather forecast to ensure goods carried by their "fresh produce" delivery vans were not wasted in large quantities. Google chairman Eric Schmidt called this "the world's first office computer", built in 1951. A subsidiary LEO Computers Ltd was formed in 1954 and went on to build 11 Leo II and 94 Leo III computers that were sold worldwide. One of the ardent users of LEO computers was the General Post Office (GPO), who bought them in the mid/late 1960s to produce telephone bills. They were kept going until 1981, helped by buying other companies' redundant machines and using them for spare parts.
== Composition and nutrition == Garlic powder is 73% carbohydrates (including 9% dietary fiber), 17% protein, 1% fat, and 6% water (table). In a reference amount of 100 g (3.5 oz), garlic powder supplies 331 calories, and is a moderate-to-rich source (higher than 10% of the Daily Value, DV) of several B vitamins and dietary minerals (table).
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.